Coave Therapeutics has raised €32 million ($33 million) in Series A financing to advance its ALIGATER™ genetic medicine platform and develop targeted therapies for various diseases.
Information on the Target
Coave Therapeutics (Coave) is a pioneering company focused on advancing genetic medicines. With its proprietary ALIGATER™ platform, Coave addresses major challenges in delivering genetic payloads to extra-hepatic tissues, enhancing specificity, safety, and delivery efficiency. This innovative platform utilizes conjugation of targeting ligands, such as small molecules, peptides, or antibody fragments, to AAV or other non-viral vectors, ultimately aiming to develop high-quality gene therapies for various diseases.
The funds raised will support Coave in advancing its lead therapeutic programs towards Clinical Trial Application (CTA) and Investigational New Drug (IND) stages. The company’s primary focus areas include treating diseases of the central nervous system (CNS), neuromuscular disorders, and ocular diseases, with plans to progress two development candidates to CTA/IND-enabling studies by 2026.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in France
The genetic medicine industry in France has been gaining momentum, with significant investments directed towards research and development. The country's rigorous regulatory framework has created an environm
Similar Deals
Codexial, Finovam Gestion, Groupe ILP, Angels Santé, Alsace Business Angels → StemInov
2026
Capagro, Hoxton Ventures, CapHorn, Demeter, Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, Station F → Phagos
2025
SPI (Sociétés de Projets Industriels), Bpifrance, Critical Path Ventures, MACSF, Capital Grand Est → RDS
2025
Novo Holdings A/S
invested in
Coave Therapeutics
in 2025
in a Series A deal
Disclosed details
Transaction Size: $33M